Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus

[1]  T. Berg,et al.  Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry , 2017, Journal of viral hepatitis.

[2]  Thomas Berg,et al.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.

[3]  R. Marinho,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[4]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[5]  K. Brouwer,et al.  Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes , 2006, Journal of Pharmacology and Experimental Therapeutics.

[6]  A. Mancuso,et al.  Pruritus in cholestatic and other liver diseases , 2003 .

[7]  T. Stojaković,et al.  Bile acid preparation and comprehensive analysis by high performance liquid chromatography-high-resolution mass spectrometry. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[8]  Stefan Zeuzem,et al.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[9]  A. Burroughs,et al.  Review article: pruritus in cholestatic and other liver diseases. , 2003, Alimentary pharmacology & therapeutics.